US FDA’s November Goal Dates Cannot Elevate 2024’s Novel Approvals To 2023 Levels

Another record-breaking year for novel approvals looks out of reach, but the six novel agents with November goal dates show the continued strength of rare disease drug development.

The FDA's November calendar includes user fee goal dates for six novel agents. (Shutterstock)

With only six novel candidates on its November 2024 user fee calendar, the US Food and Drug Administration is running out of chances to reach its 2023 total of 72 new molecular entities and novel biologic approvals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?